[1] Castillejos-Molina RA,Gabilondo-Navarro FB. Prostate cancer[J].Salud Publica Mex,2016, 58(2): 279-284. [2] Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients[J].Hum Pathol,2000, 31(5): 578-583. [3] Shiozawa Y, Pedersen EA, Patel L R, et al. GAS6/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche[J].Neoplasia,2010, 12(2): 116-127. [4] Mazo I B and Von Andrian U H. Adhesion and homing of blood-borne cells in bone marrow microvessels[J].J Leukoc Biol,1999, 66(1): 25-32. [5] Miftakhova R, Hedblom A, Semenas J, et al. Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow[J].Cancer Res,2016, 76(8): 2453-2464. [6] Chu G C Y, Zhau H Y E, Wang R X, et al. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization[J].Endocr Relat Cancer,2014, 21(2): 311-326. [7] Dimitroff C J, Descheny L, Trujillo N, et al. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells[J].Cancer Res,2005, 65(13): 5750-5760. [8] Barthel SR, Hays DL, Yazawa EM, et al. Definition of Molecular Determinants of Prostate Cancer Cell Bone Extravasation[J].Cancer Res,2013, 73(2): 942-952. [9] Shiozawa Y and Taichman R S. Getting blood from bone: An emerging understanding of the role that osteoblasts play in regulating hematopoietic stem cells within their niche[J].Exp Hematol,2012, 40(9): 685-694. [10] Cojoc M, Peitzsch C, Trautmann F, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis[J].Onco Targets Ther,2013, 6:1347-1361. [11] Conley-Lacomb MK, Semaan L, Singareddy R, et al. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis[J].Mol Cancer,2016, 15(1),68. [12] Singh R, Kapur N, Mir H, et al. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and alpha(v)beta(3) integrin clustering[J].Oncotarget,2016, 7(6): 7343-7353. [13] Morrissey C, Vessella RL, Lange PH, et al. The biology and clinical implications of prostate cancer dormancy and metastasis[J].J Mol Med(Berl),2016, 94(3): 259-265. [14] Taichman RS, Patel LR, Bedenis R, et al. GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation[J].PLoS One,2013, 8(4): 10. [15] Cackowski F, Eber MR, Rhee J, et al. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy[J].J Cell Biochem,2016, 118(4):891-902. [16] Nakamura T, Shinriki S, Jono H, et al. Intrinsic TGF-beta 2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells[J].Oncotarget,2015, 6(2): 1008-1019. [17] Condeelis J,Pollard J W. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis[J].Cell,2006, 124(2): 263-266. [18] Kim SW, Kim JS, Papadopoulos J, et al. Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse[J].Int Immunopharmacol,2011, 11(7): 862-872. [19] Browne G, Taipaleenmaki H, Stein GS, et al. MicroRNAs in the control of metastatic bone disease[J].Trends Endocrinol Metab,2014, 25(6): 320-327. [20] Wu MY, Li CJ, Yiang GT, et al. Molecular Regulation of Bone Metastasis Pathogenesis[J].Cell Physiol Biochem,2018, 46(4): 1423-1438. [21] Kagiya T. MicroRNAs,Osteolytic Bone Metastasis.The roles of MicroRNAs in tumor-induced osteoclast differentiation[J].J Clin Medx,2015, 4(9): 1741-1752. [22] Meng XQ. Loss of TGF-beta signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis[J].Cancer Lett,2018, 418:109-118. [23] Lee C. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis[J].Cancer Lett,2018, 414:205-213. [24] Lu Y, Cai Z, Xiao GZ, et al. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption[J].Cancer Res,2007, 67(8): 3646-3653. [25] Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1 alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease[J].Blood,2003, 102(1): 311-319. [26] Bendre M S, Montague D C, Peery T, et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease[J].Bone,2003, 33(1): 28-37. [27] Gao L, Wu GJ, Liu XW, et al. Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene[J].Cancer Lett,2011, 310(1): 94-100. [28] Gravina GL, Mancini A, Muzi P, et al. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models[J].Prostate,2015, 75(12): 1227-1246.
2020, Vol. 37 
